NASDAQ: CRNX | Healthcare / Biotechnology / USA |
33.23 | -0.2700 | -0.81% | Vol 1.09M | 1Y Perf 84.67% |
Dec 6th, 2023 16:00 DELAYED |
BID | 31.63 | ASK | 34.96 | ||
Open | 33.75 | Previous Close | 33.50 | ||
Pre-Market | - | After-Market | 33.19 | ||
- - | -0.04 -0.12% |
Target Price | 38.50 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 15.86 | Finscreener Ranking | ★★+ 47.16 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 55.76 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★+ 42.70 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 96.67 | Earnings Rating | Neutral | |
Market Cap | 2.22B | Earnings Date | 13th Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.16 | |
Beta | 0.56 |
Today's Price Range 33.1034.09 | 52W Range 15.2333.85 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 4.53% | ||
1 Month | 12.57% | ||
3 Months | 105.63% | ||
6 Months | 50.36% | ||
1 Year | 84.67% | ||
3 Years | 140.10% | ||
5 Years | -0.18% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -39.03 | |||
ROE last 12 Months | -58.10 | |||
ROA (5Y Avg) | -18.67 | |||
ROA last 12 Months | -53.26 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -55.09 | |||
Return on invested Capital Q | -11.67 | |||
Return on invested Capital Y | -11.61 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 2.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-5.90 | ||||
2.71 | ||||
223.36 | ||||
- | ||||
-11.70 | ||||
-2.06 | ||||
2.71 | ||||
6.53 | ||||
587.94M | ||||
Forward PE | -9.46 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
15.10 | ||||
15.40 | ||||
0.01 | ||||
0.01 | ||||
- | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-2 961.50 | ||||
-2 943.10 | ||||
-22 521.60 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.03M | ||||
0.07 | ||||
-40.33 | ||||
-21.29 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | -0.89 | -1.01 | -13.48 |
Q02 2023 | -0.85 | -0.94 | -10.59 |
Q01 2023 | -0.82 | -0.85 | -3.66 |
Q04 2022 | -0.82 | -0.84 | -2.44 |
Q03 2022 | -0.78 | -0.78 | 0.00 |
Q02 2022 | -0.62 | -0.81 | -30.65 |
Q01 2022 | -0.56 | -0.73 | -30.36 |
Q04 2021 | -0.57 | -0.68 | -19.30 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -0.90 | 3.23 | Positive |
12/2023 FY | -3.66 | 0.54 | Positive |
3/2024 QR | -0.89 | 0.00 | - |
12/2024 FY | -3.46 | 10.13 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.89 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.09M |
Shares Outstanding | 66.80K |
Shares Float | 53.91M |
Trades Count | 10.72K |
Dollar Volume | 36.56M |
Avg. Volume | 1.03M |
Avg. Weekly Volume | 798.81K |
Avg. Monthly Volume | 734.51K |
Avg. Quarterly Volume | 1.56M |
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) stock closed at 33.23 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 1.09M shares and market capitalization of 2.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Crinetics Pharmaceuticals Inc. CEO is R. Scott Struthers.
The one-year performance of Crinetics Pharmaceuticals Inc. stock is 84.67%, while year-to-date (YTD) performance is 81.58%. CRNX stock has a five-year performance of -0.18%. Its 52-week range is between 15.23 and 33.85, which gives CRNX stock a 52-week price range ratio of 96.67%
Crinetics Pharmaceuticals Inc. currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 2.71, a price-to-sale (PS) ratio of 223.36, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -53.26%, a ROC of -55.09% and a ROE of -58.10%. The company’s profit margin is -%, its EBITDA margin is -2 943.10%, and its revenue ttm is $4.03 Million , which makes it $0.07 revenue per share.
Of the last four earnings reports from Crinetics Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Crinetics Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Crinetics Pharmaceuticals Inc. is Strong Buy (1), with a target price of $38.5, which is +15.86% compared to the current price. The earnings rating for Crinetics Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Crinetics Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Crinetics Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.56, ATR14 : 1.51, CCI20 : 115.38, Chaikin Money Flow : 0.11, MACD : 1.28, Money Flow Index : 79.89, ROC : 10.80, RSI : 65.20, STOCH (14,3) : 86.86, STOCH RSI : 0.73, UO : 55.36, Williams %R : -13.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Crinetics Pharmaceuticals Inc. in the last 12-months were: Betz Stephen (Sold 20 714 shares of value $446 028 ), Coelho Rogerio Vivaldi (Buy at a value of $110 300), Dana Pizzuti (Sold 8 212 shares of value $132 624 ), Krasner Alan (Sold 0 shares of value $-84 070 ), Krasner Alan (Sold 7 000 shares of value $210 000 ), Marcus Wilson (Sold 0 shares of value $-278 400 ), Marcus Wilson (Sold 40 922 shares of value $904 903 ), Stephen F. Betz (Sold 20 840 shares of value $400 524 ), Struthers Richard (Sold 0 shares of value $-1 970 600 ), Struthers Richard (Sold 200 000 shares of value $6 111 440 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CEO: R. Scott Struthers
Telephone: +1 858 450-6464
Address: 10222 Barnes Canyon Road, San Diego 92121, CA, US
Number of employees: 68
Wed, 08 Nov 2023 16:40 GMT Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Crinetics Pharmaceuticals (CRNX) and PolyPid (PYPD)
- TipRanks. All rights reserved.Mon, 11 Sep 2023 12:51 GMT Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Acrivon Therapeutics, Inc. (ACRV)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.